Quick Answer
Lineage Cell Therapeutics, Inc. reported Total Revenue of $14.56 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.56M +53.2% |
$9.50M +6.2% |
$8.95M -39.2% |
$14.70M +238.7% |
$4.34M +137.7% |
$1.83M |
| Revenue (ASC 606) | $14.56M +53.2% |
$9.50M +6.2% |
$8.95M -39.2% |
$14.70M | — | — |
| Net Income | -$63.53M -241.4% |
-$18.61M +13.4% |
-$21.49M +18.2% |
-$26.27M +38.9% |
-$43.02M -108.3% |
-$20.65M -76.4% |
| Diluted EPS | -$0.28 -211.1% |
-$0.09 +25.0% |
-$0.12 +20.0% |
-$0.15 | — | — |
| Total Assets | $112.58M -0.6% |
$113.22M +12.1% |
$101.02M -18.3% |
$123.66M -29.2% |
$174.54M +61.7% |
$107.95M -14.0% |
| Cash and Equivalents | $40.79M -10.9% |
$45.79M +29.2% |
$35.44M +212.1% |
$11.36M -79.6% |
$55.74M +71.1% |
$32.59M +243.1% |
| Stockholders Equity | $44.55M -43.2% |
$78.38M +23.6% |
$63.42M -13.5% |
$73.34M -20.5% |
$92.22M -4.1% |
$96.20M -14.8% |
| R&D Expense | $17.73M +42.2% |
$12.47M -20.6% |
$15.71M +12.3% |
$13.99M -58.8% |
$33.91M +175.3% |
$12.32M -31.4% |
| Operating Income | -$36.62M -70.5% |
-$21.48M +13.2% |
-$24.73M -9.8% |
-$22.52M +54.2% |
-$49.21M -86.1% |
-$26.45M +32.0% |
| Gross Profit | — | — | $8.27M -40.8% |
$13.97M +379.4% |
$2.92M +102.3% |
$1.44M -53.6% |
| Shares Outstanding | 243.12M +10.3% |
220.42M +26.0% |
174.99M +2.9% |
170.09M +0.4% |
169.48M +10.7% |
153.10M +2.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.68M | -2.6% | +33.1% |
| Revenue (ASC 606) | September 30, 2025 | $3.68M | -2.6% | +33.1% |
| Net Income | September 30, 2025 | -$29.78M | -881.6% | +2.2% |
| Diluted EPS | September 30, 2025 | -$0.13 | -550.0% | +0.0% |
| Total Assets | September 30, 2025 | $89.64M | -7.2% | -1.3% |
| Cash and Equivalents | September 30, 2025 | $40.46M | +45.8% | -4.3% |
| Stockholders Equity | September 30, 2025 | $22.04M | -66.7% | -54.4% |
| R&D Expense | September 30, 2025 | $3.27M | +3.2% | +5.3% |
| Operating Income | September 30, 2025 | -$3.79M | +1.4% | +80.9% |
| Gross Profit | September 30, 2023 | $1.08M | -61.0% | -65.2% |
| Shares Outstanding | September 30, 2025 | 230.33M | +22.0% | +0.9% |
- Lineage Cell Therapeutics, Inc. reported Total Revenue of $14.56 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Total Revenue compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Revenue (ASC 606) of $14.56 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Net Income of -$63.53 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -241.4% in Net Income compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Diluted EPS of $0.28 per share (loss) for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -211.1% in Diluted EPS compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Total Assets of $112.58 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -0.6% in Total Assets compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Cash and Equivalents of $40.79 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -10.9% in Cash and Equivalents compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Stockholders Equity of $44.55 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -43.2% in Stockholders Equity compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported R&D Expense of $17.73 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +42.2% in R&D Expense compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Operating Income of -$36.62 million for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -70.5% in Operating Income compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Gross Profit of $8.27 million for fiscal year 2023.
- Lineage Cell Therapeutics, Inc. showed a decrease of -40.8% in Gross Profit compared to the prior fiscal year.
- Lineage Cell Therapeutics, Inc. reported Shares Outstanding of 243.12 million shares for fiscal year 2025.
- Lineage Cell Therapeutics, Inc. showed an increase of +10.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: